<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089140</url>
  </required_header>
  <id_info>
    <org_study_id>1000013524</org_study_id>
    <nct_id>NCT01089140</nct_id>
  </id_info>
  <brief_title>Non-Idiopathic Scoliosis Treated With Tranexamic Acid</brief_title>
  <official_title>Blood Loss and Transfusion Requirement in Pediatric Patients With Non-Idiopathic Scoliosis Treated With Tranexamic Acid Undergoing Posterior Spinal Instrumentation and Fusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of tranexamic acid (TXA) for reducing perioperative blood loss and transfusion
      requirement in pediatric patients with secondary scoliosis undergoing posterior spinal
      fusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate whether tranexamic acid (TXA) reduces perioperative blood loss and transfusion
      requirement in pediatric patients with secondary scoliosis undergoing posterior spinal
      fusion.In addition determination of the optimal TXA dosing for perioperative reduction of
      blood loss and transfusion requirement as well as to evaluate use of thromboelastography
      (TEG) as a measure of coagulation and fibrinolysis in pediatric patients with secondary
      scoliosis undergoing posterior spinal fusion (this may help guide blood product therapy).

      The investigation will determine the effects of TXA on the TEG profile and whether
      plasminogen activator inhibitor-1 (PAI-1) level affects bleeding and transfusion requirement
      during scoliosis surgery. Finally to investigate whether PAI-1 level affects bleeding in
      response to TXA during scoliosis surgery.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative blood loss and transfusion requirement</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thromboelastography (TEG): TEG monitors coagulation of blood samples in vitro to produce a complete picture of clot formation, strength and dissolution (i.e. fibrinolysis).</measure>
    <time_frame>After Induction- Prior to Drug Administration, Immediately after Bolus Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor-1</measure>
    <time_frame>Baseline -Immediately after induction and prior to administration of study drug</time_frame>
    <description>Different genotypes for the plasminogen activator inhibitor-1 (PAI-1) gene may have varying degrees of bleeding. PAI-1 inhibits the transformation of plasminogen to plasmin thereby decreasing plasmin-induced fibrinolysis. Thus, PAI-1 promotes clot stability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Non-idiopathic Scoliosis</condition>
  <arm_group>
    <arm_group_label>. Tranexamic acid low dose 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid 100mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid 10mg/kg/hr</intervention_name>
    <description>Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator</description>
    <arm_group_label>. Tranexamic acid low dose 10 mg/kg</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid 100 mg/kg/h infusion</intervention_name>
    <description>Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.</description>
    <arm_group_label>Tranexamic acid 100mg/kg</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Saline placebo</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Children with secondary scoliosis undergoing posterior spinal fusion

        Exclusion Criteria:

          1. Known bleeding disorder as this may increase the risk of bleeding

          2. Current antifibrinolytic therapy as these patients may bleed less

          3. Patient or family history of thromboembolic disease as there may be potential risk of
             thrombosis

          4. Use of NSAIDS within 5 days of surgery as this may increase the risk of bleeding

          5. Known allergy to TXA

          6. History of renal insufficiency as TXA is renally excreted

          7. Colour vision disturbance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara Der, M.sc. MD.,(FRCPC)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for SickkIds</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Tara Der</investigator_full_name>
    <investigator_title>Staff Anaesthesiologist</investigator_title>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>scoliosis</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>Investigating non-idiopathic scoliosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

